Biomerica (Biomerica) Float Percentage Of Total Shares Outstanding : 92.71% (As of Apr. 29, 2024)

View and export this data going back to 1978. Start your Free Trial

What is Biomerica Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biomerica's float shares is 15.59 Mil. Biomerica's total shares outstanding is 16.82 Mil. Biomerica's float percentage of total shares outstanding is 92.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biomerica's Insider Ownership is 11.22%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biomerica's Institutional Ownership is 14.09%.

Biomerica Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Biomerica's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	15.59	/	16.82
	=	92.71%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomerica (Biomerica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

17571 Von Karman Avenue, Irvine, CA, USA, 92614

Website

https://www.biomerica.com

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.

Executives

John P. Kenny	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani	director, officer: Cheif Executive Officer	17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu	officer: Chief Financial Officer	12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri	director
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan	officer: Chief Financial Officer	114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio	officer: President-diagnostics	1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore	director, 10 percent owner, officer: Secretary	1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson	director	1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider	other: Greater than 5% holder	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The	other: Greater than 5% holder	7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm	director	1533 MONROVIA AVE., NEWPORT BEACH CA 92663